<DOC>
	<DOC>NCT01419015</DOC>
	<brief_summary>A single arm, prospective multicenter non-randomized pivotal clinical trial evaluating the 20mm Edwards SAPIEN XT™ transcatheter heart valve (model 9300TFX), NovaFlex™ transfemoral delivery system, and crimper accessories. The trial includes a premarket pivotal cohort to evaluate the system performance as well as a post market clinical follow-up phase involving long term follow-up of all patients to evaluate the safety of investigational devices up to 5 years.</brief_summary>
	<brief_title>PREVAIL-20J - Transfemoral Placement of 20mm Aortic Balloon Expandable Transcatheter Valve Trial</brief_title>
	<detailed_description>Purpose: To evaluate the safety and efficacy of THV-9300 (20mm) for patients who have severe symptomatic aortic stenosis attributed to calcification and degeneration of a valve leaflet and for whom undergoing a surgery safely would be difficult. Enrollment: 15 patients (No.of patients needed: 12) Follow-up: Subject data collection will include clinical information at baseline and during the index procedure. Subjects will undergo clinical follow-up at discharge, 30 days, 6 months and annually for 5 years. Clinical sites: 1)Osaka University Hospital, 2)Kurashiki Central Hospital, 3)Sakakibara Heart Institute, 4) Kokura Memorial Hospital</detailed_description>
	<mesh_term>Constriction, Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Patients who were judged difficult to safely undergo AVR Severe senile degenerative aortic valve stenosis NYHA Functional Class II or greater Signed Informed Consent Aortic valve is congenital unicuspid or bicuspid Annulus size between &lt; 16 mm or &gt; 19 mm LVEF &lt; 20 %</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>SAPIEN XT Valve (20mm)</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Valvular Heart Disease</keyword>
	<keyword>Aortic Stenosis</keyword>
	<keyword>Heart Valve Therapy</keyword>
	<keyword>Transcatheter</keyword>
	<keyword>Transfemoral</keyword>
	<keyword>Efficacy endpoints</keyword>
	<keyword>Indexed Aortic Valve Area</keyword>
	<keyword>NYHA</keyword>
</DOC>